FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, reported that Janssen Supply Group, LLC, a Johnson & Johnson company, has committed to a large-scale manufacturing suite at its biopharmaceutical manufacturing facility in Holly Springs, NC, which is set to be fully operational in 2025.

The long-term commitment is an extension of an existing relationship and will support manufacturing of Janssen’s clinical and commercial pipeline.

“This commitment recognizes the innovation and expertise that FUJIFILM Diosynth Biotechnologies is uniquely positioned to deliver,” said Toshihisa Iida, corporate vice president of FUJIFILM Corporation and chairman of FUJIFILM Diosynth Biotechnologies. “FUJIFILM Diosynth Biotechnologies is in the process of increasing capacity more than five times through a commitment of up to $7 billion in manufacturing capability across Europe and U.S.”

Lars Petersen, president and chief executive officer, FUJIFILM Diosynth Biotechnologies said, “We are pleased to be able to expand this collaboration into our new state-of-the-art facility in Holly Springs, NC. This underscores our unwavering commitment to be a long-term partner development and manufacturing organization (PDMO) in the advancement of medicines for patients around the world.”